Company profile
Contineum Therapeutics, Inc.
NASDAQ: CTNM · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
57CFH 69DQ 42GM —SS 45
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ revenue growth (YoY), disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$60.0M
Employees
51
as of 2026-08-11
Market cap
$545.1M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02024
Net income-$60.0M-$60.0M2025
Operating income-$68.1M-$68.1M2025
Total assets$276.6M$276.6M2025
Liabilities$15.7M$15.7M2025
Equity$261.0M$261.0M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Contineum Therapeutics, Inc.’s revenue?
Contineum Therapeutics, Inc. booked $0 in FY2024 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Achieve Life Sciences, Inc.37DNeurogene Inc.43DArtiva Biotherapeutics, Inc.41DNika Pharmaceuticals Inc.29DBenitec Biopharma Inc.47DLarimar Therapeutics, Inc.38DNeighbors
San Diego →Key facts
CEOCarmine N. Stengone
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: CTNM
Employees51
IPO date2024-04-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.